Free Newsletter
Lilly beset by potential Strattera imitators
Free newsletter via e-mail
Tools
Strattera poachers are besieging Eli Lilly on all sides. Sandoz, the Novartis generics unit, is challenging Lilly's patent on the hyperactivity drug, set to expire in 2017, in federal court. Sandoz is seeking a pre-emptive ruling to protect its copycat version of Strattera. This comes after Lilly filed suit against Iceland-based Actavis Group to block that company's Strattera generic. And no wonder Lilly's so protective: the drug generated $282 million for the company during the first half of 2007.
- here's the report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
